- Home
- MRKR vs CLRB Comparison
MRKR vs CLRB Comparison
Compare MRKR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- CLRB
- Stock Information
- Founded
- MRKR N/A
- CLRB 2002
- Country
- MRKR United States
- CLRB United States
- Employees
- MRKR N/A
- CLRB N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- CLRB Health Care
- Exchange
- MRKR Nasdaq
- CLRB Nasdaq
- Market Cap
- MRKR 19.1M
- CLRB 17.6M
- IPO Year
- MRKR N/A
- CLRB N/A
- Fundamental
- Price
- MRKR $1.71
- CLRB $4.88
- Analyst Decision
- MRKR Strong Buy
- CLRB Hold
- Analyst Count
- MRKR 3
- CLRB 2
- Target Price
- MRKR $13.17
- CLRB N/A
- AVG Volume (30 Days)
- MRKR 102.6K
- CLRB 198.9K
- Earning Date
- MRKR 08-13-2025
- CLRB 08-12-2025
- Dividend Yield
- MRKR N/A
- CLRB N/A
- EPS Growth
- MRKR N/A
- CLRB N/A
- EPS
- MRKR N/A
- CLRB N/A
- Revenue
- MRKR $5,696,123.00
- CLRB N/A
- Revenue This Year
- MRKR N/A
- CLRB N/A
- Revenue Next Year
- MRKR $11.28
- CLRB N/A
- P/E Ratio
- MRKR N/A
- CLRB N/A
- Revenue Growth
- MRKR 71.53
- CLRB N/A
- 52 Week Low
- MRKR $0.95
- CLRB $4.36
- 52 Week High
- MRKR $5.99
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- MRKR 60.22
- CLRB 34.07
- Support Level
- MRKR $1.56
- CLRB $4.62
- Resistance Level
- MRKR $1.93
- CLRB $5.05
- Average True Range (ATR)
- MRKR 0.10
- CLRB 0.88
- MACD
- MRKR 0.02
- CLRB -0.35
- Stochastic Oscillator
- MRKR 57.69
- CLRB 8.92
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.